TenNor Therapeutics
Tennorx is a leading enterprise focused on the development of new drugs in the fields of bacterial infections and metabolic diseases. It has an experienced, international research and development management team leading global new drug R&D efforts. The company possesses a unique multi-target conjugate molecule technology platform and a global intellectual property protected pipeline, with several products in late-stage clinical trials for indications including Helicobacter pylori infection, implantable medical device infections, liver cirrhosis hepatic encephalopathy, and diarrhea-predominant irritable bowel syndrome.
Industries
Nr. of Employees
medium (51-250)
TenNor Therapeutics
Westfield, New Jersey, United States, North America
Patents
such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections
US-7884099-B2
View Details
such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections
US-7884099-B2
View DetailsProducts
Therapeutic candidate for Helicobacter pylori infection
A novel small‑molecule candidate under clinical development for treatment of Helicobacter pylori infection.
Therapeutic candidate for implantable medical device infection
Drug candidate aimed at preventing or treating infections associated with implanted medical devices; progressed into clinical development.
Therapeutic candidate for hepatic encephalopathy in cirrhosis
A clinical‑stage candidate intended to treat hepatic encephalopathy associated with liver cirrhosis.
Therapeutic candidate for diarrhea‑predominant irritable bowel syndrome (IBS‑D)
Clinical‑stage candidate intended to treat diarrhea‑predominant irritable bowel syndrome.
Intra‑articular candidate for prosthetic joint infection (Phase II)
A candidate administered via intra‑articular injection being evaluated in a Phase II clinical trial for treatment of prosthetic joint infection.
Therapeutic candidate for Helicobacter pylori infection
A novel small‑molecule candidate under clinical development for treatment of Helicobacter pylori infection.
Therapeutic candidate for implantable medical device infection
Drug candidate aimed at preventing or treating infections associated with implanted medical devices; progressed into clinical development.
Therapeutic candidate for hepatic encephalopathy in cirrhosis
A clinical‑stage candidate intended to treat hepatic encephalopathy associated with liver cirrhosis.
Therapeutic candidate for diarrhea‑predominant irritable bowel syndrome (IBS‑D)
Clinical‑stage candidate intended to treat diarrhea‑predominant irritable bowel syndrome.
Intra‑articular candidate for prosthetic joint infection (Phase II)
A candidate administered via intra‑articular injection being evaluated in a Phase II clinical trial for treatment of prosthetic joint infection.
Services
Execution and management of clinical studies for investigational drug candidates, including mid‑stage trial initiation.
Execution and management of clinical studies for investigational drug candidates, including mid‑stage trial initiation.
Expertise Areas
- Antibacterial drug development
- Therapeutics for metabolic‑related diseases
- Clinical development (Phase II/III)
- Small‑molecule conjugate platform development
Key Technologies
- Multi‑target conjugate chemistry
- Small‑molecule drug discovery
- Clinical trial design and conduct
- Formulation for intra‑articular and route‑specific delivery
News & Updates
丹诺医药在2025年荣登BEYOND Awards医疗科技超越榜。
2025年5月12日，北医三院的周丽雅和宋志强教授团队报道了多项与幽门螺杆菌相关的新药、新方案及新评价指标的研究结果。
2025年5月10日，丹诺医药荣登2025未来医疗100强双榜单。
2025年5月7日，丹诺医药的幽门螺杆菌首创新药利福特尼唑在美国消化疾病周亮相。
2025年3月24日，丹诺医药启动了TNP-2092关节腔注射给药治疗人工关节感染的II期临床试验。
丹诺医药荣登BEYOND Awards医疗科技超越榜。
丹诺医药在2025年荣登BEYOND Awards医疗科技超越榜。
2025年5月12日，北医三院的周丽雅和宋志强教授团队报道了多项与幽门螺杆菌相关的新药、新方案及新评价指标的研究结果。
2025年5月10日，丹诺医药荣登2025未来医疗100强双榜单。
2025年5月7日，丹诺医药的幽门螺杆菌首创新药利福特尼唑在美国消化疾病周亮相。
2025年3月24日，丹诺医药启动了TNP-2092关节腔注射给药治疗人工关节感染的II期临床试验。
丹诺医药荣登BEYOND Awards医疗科技超越榜。